The complex pathway between amyloid β and cognition: implications for therapy
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The aberrant aggregation of amyloid-β (Aβ) is a central pathological marker of Alzheimer's disease (AD) and shows different neurotoxic properties in various forms, such as monomers, oligomers, fibers and plaques.”
From Molecular design of MRI probes for targeting amyloid-β species: from in vitro binding to in vivo imaging (2026) · cites this paper as [3]
In the citing paper
“These peptides are initially present in the form of soluble monomers, then aggregate to form oligomers and protofibrils, and end up forming insoluble plaques within the brain 3, 4.”
From Molecular design of MRI probes for targeting amyloid-β species: from in vitro binding to in vivo imaging (2026) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationScheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chételat, G., Teunissen, C. E., Cummings, J., & van der Flier, W. M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32205-4 · Cited by 5,465
Self-citationJack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Self-citationClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Ngandu, T., Lehtisalo, J., Solomon, A., Levälahti, E., Ahtiluoto, S., Antikainen, R., Bäckman, L., Hänninen, T., Jula, A., Laatikainen, T., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60461-5 · Cited by 3,689
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Leng, F., & Edison, P. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00435-y · Cited by 3,179
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Villemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., Szoeke, C., Macaulay, S. L., Martins, R., Maruff, P., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70044-9 · Cited by 2,279
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Feldman, H. H., Frisoni, G. B., Hampel, H., Jagust, W. J., Johnson, K. A., Knopman, D. S., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002923 · Cited by 1,864
Self-citationDonanemab in Early Alzheimer’s Disease
Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728
Research works printed but not linked: 54
- Hardy, 2002, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics, Science, 297, 353, 10.1126/science.1072994 · DOI · Paper page
- Aisen, 2020, The future of anti-amyloid trials, J Prev Alzheimers Dis, 7, 146, 10.14283/jpad.2020.24 · DOI · Paper page
- Ackley, 2021, Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis, BMJ, 372, n156, 10.1136/bmj.n156 · DOI · Paper page
- Budd Haeberlein, 2022, Two randomized phase 3 studies of aducanumab in early Alzheimer's disease, J Prev Alzheimers Dis, 9, 197, 10.14283/jpad.2022.30 · DOI · Paper page
- van Dyck, 2023, Lecanemab in early Alzheimer's disease, N Engl J Med, 388, 9, 10.1056/NEJMoa2212948 · DOI · Paper page
- Villemagne, 2018, Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions, Nat Rev Neurol, 14, 225, 10.1038/nrneurol.2018.9 · DOI · Paper page
- Boulo, 2020, First amyloid β1-42 certified reference material for re-calibrating commercial immunoassays, Alzheimers Dement, 16, 1493, 10.1002/alz.12145 · DOI · Paper page
- Morris, 2022, Autosomal dominant and sporadic late onset Alzheimer's disease share a common in vivo pathophysiology, Brain, 145, 3594, 10.1093/brain/awac181 · DOI · Paper page
- Farrell, 2022, Association of emerging β-amyloid and tau pathology with early cognitive changes in clinically normal older adults, Neurology, 98, e1512, 10.1212/WNL.0000000000200137 · DOI
- Tideman, 2022, Association of β-amyloid accumulation with executive function in adults with unimpaired cognition, Neurology, 98, e1525, 10.1212/WNL.0000000000013299 · DOI
- Pereira, 2021, Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer's disease, Brain, 144, 310, 10.1093/brain/awaa395 · DOI · Paper page
- Betthauser, 2020, Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age, Brain, 143, 320, 10.1093/brain/awz378 · DOI · Paper page
- Chen, 2021, Regional tau effects on prospective cognitive change in cognitively normal older adults, J Neurosci, 41, 366, 10.1523/JNEUROSCI.2111-20.2020 · DOI
- Harrison, 2021, Distinct effects of beta-amyloid and tau on cortical thickness in cognitively healthy older adults, Alzheimers Dement, 17, 1085, 10.1002/alz.12249 · DOI
- Guo, 2021, Longitudinal cognitive and biomarker measurements support a unidirectional pathway in Alzheimer's disease pathophysiology, Biol Psychiatry, 89, 786, 10.1016/j.biopsych.2020.06.029 · DOI · Paper page
- Weigand, 2020, Is tau in the absence of amyloid on the Alzheimer's continuum?: a study of discordant PET positivity, Brain Commun, 2, 10.1093/braincomms/fcz046 · DOI · Paper page
- Yoon, 2022, Abnormal tau in amyloid PET negative individuals, Neurobiol Aging, 109, 125, 10.1016/j.neurobiolaging.2021.09.019 · DOI
- Strikwerda-Brown, 2022, Association of elevated amyloid and tau positron emission tomography signal with near-term development of Alzheimer disease symptoms in older adults without cognitive impairment, JAMA Neurol, 79, 975, 10.1001/jamaneurol.2022.2379 · DOI · Paper page
- Wardlaw, 2013, Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration, Lancet Neurol, 12, 822, 10.1016/S1474-4422(13)70124-8 · DOI · Paper page
- Koncz, 2018, Are the brain's vascular and Alzheimer pathologies additive or interactive?, Curr Opin Psychiatry, 31, 147, 10.1097/YCO.0000000000000395 · DOI
- Soldan, 2020, White matter hyperintensities and CSF Alzheimer disease biomarkers in preclinical Alzheimer disease, Neurology, 94, e950, 10.1212/WNL.0000000000008864 · DOI · Paper page
- DeCarli, 2019, Vascular burden score impacts cognition independent of amyloid PET and MRI measures of Alzheimer's disease and vascular brain injury, J Alzheimers Dis, 68, 187, 10.3233/JAD-180965 · DOI
- Altendahl, 2020, An IL-18-centered inflammatory network as a biomarker for cerebral white matter injury, PLoS One, 15, 10.1371/journal.pone.0227835 · DOI
- Hughes, 2013, Pulse wave velocity is associated with β-amyloid deposition in the brains of very elderly adults, Neurology, 81, 1711, 10.1212/01.wnl.0000435301.64776.37 · DOI · Paper page
- Reed, 2012, Coronary risk correlates with cerebral amyloid deposition, Neurobiol Aging, 33, 1979, 10.1016/j.neurobiolaging.2011.10.002 · DOI · Paper page
- Rapp, 2020, Effects of intensive versus standard blood pressure control on domain-specific cognitive function: a substudy of the SPRINT randomised controlled trial, Lancet Neurol, 19, 899, 10.1016/S1474-4422(20)30319-7 · DOI · Paper page
- Kim, 2018, Assessment of extent and role of tau in subcortical vascular cognitive impairment using 18F-AV1451 positron emission tomography imaging, JAMA Neurol, 75, 999, 10.1001/jamaneurol.2018.0975 · DOI · Paper page
- Hu, 2022, Tau pathologies mediate the association of blood pressure with cognitive impairment in adults without dementia: the CABLE study, Alzheimers Dement, 18, 53, 10.1002/alz.12377 · DOI
- Thomas, 2020, Association of TDP-43 proteinopathy, cerebral amyloid angiopathy, and Lewy bodies with cognitive impairment in individuals with or without Alzheimer's disease neuropathology, Sci Rep, 10, 10.1038/s41598-020-71305-2 · DOI · Paper page
- Nelson, 2022, Frequency of LATE neuropathologic change across the spectrum of Alzheimer's disease neuropathology: combined data from 13 community-based or population-based autopsy cohorts, Acta Neuropathol, 144, 27, 10.1007/s00401-022-02444-1 · DOI · Paper page
- Power, 2018, Combined neuropathological pathways account for age-related risk of dementia, Ann Neurol, 84, 10, 10.1002/ana.25246 · DOI · Paper page
- Filshtein, 2019, Neuropathological diagnoses of demented Hispanic, Black, and non-Hispanic White decedents seen at an Alzheimer's disease center, J Alzheimers Dis, 68, 145, 10.3233/JAD-180992 · DOI · Paper page
- Wilkins, 2022, Racial and ethnic differences in amyloid PET positivity in individuals with mild cognitive impairment or dementia: a secondary analysis of the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) cohort study, JAMA Neurol, 79, 1139, 10.1001/jamaneurol.2022.3157 · DOI · Paper page
- Boyle, 2021, To what degree is late life cognitive decline driven by age-related neuropathologies?, Brain, 144, 2166, 10.1093/brain/awab092 · DOI · Paper page
- Brosseron, 2022, Soluble TAM receptors sAXL and sTyro3 predict structural and functional protection in Alzheimer's disease, Neuron, 110, 1009, 10.1016/j.neuron.2021.12.016 · DOI · Paper page
- Whitwell, 2018, Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease, Alzheimers Dement, 14, 1005, 10.1016/j.jalz.2018.02.020 · DOI · Paper page
- Rabin, 2019, Vascular risk and β-amyloid are synergistically associated with cortical tau, Ann Neurol, 85, 272, 10.1002/ana.25399 · DOI · Paper page
- Koscik, 2020, Amyloid duration is associated with preclinical cognitive decline and tau PET, Alzheimers Dement, 12
- Schindler, 2021, Predicting symptom onset in sporadic Alzheimer disease with amyloid PET, Neurology, 97, e1823, 10.1212/WNL.0000000000012775 · DOI · Paper page
- Das, 2021, Tau-atrophy variability reveals phenotypic heterogeneity in Alzheimer's disease, Ann Neurol, 90, 751, 10.1002/ana.26233 · DOI · Paper page
- Arenaza-Urquijo, 2018, Resistance vs resilience to Alzheimer disease: clarifying terminology for preclinical studies, Neurology, 90, 695, 10.1212/WNL.0000000000005303 · DOI · Paper page
- Hohman, 2016, Asymptomatic Alzheimer disease: defining resilience, Neurology, 87, 2443, 10.1212/WNL.0000000000003397 · DOI · Paper page
- Seto, 2022, Exploring common genetic contributors to neuroprotection from amyloid pathology, Brain Commun, 4, 10.1093/braincomms/fcac066 · DOI
- La Joie, 2021, Association of APOE4 and clinical variability in Alzheimer disease with the pattern of tau- and amyloid-PET, Neurology, 96, e650, 10.1212/WNL.0000000000011270 · DOI · Paper page
- Weigand, 2021, APOE interacts with tau PET to influence memory independently of amyloid PET in older adults without dementia, Alzheimers Dement, 17, 61, 10.1002/alz.12173 · DOI · Paper page
- Chhatwal, 2022, Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study, Lancet Neurol, 21, 140, 10.1016/S1474-4422(21)00375-6 · DOI · Paper page
- Jagust, 2021, Temporal dynamics of β-amyloid accumulation in aging and Alzheimer disease, Neurology, 96, e1347, 10.1212/WNL.0000000000011524 · DOI · Paper page
- Landau, 2018, Memory decline accompanies subthreshold amyloid accumulation, Neurology, 90, e1452, 10.1212/WNL.0000000000005354 · DOI · Paper page
- Farrell, 2018, Regional amyloid accumulation and cognitive decline in initially amyloid-negative adults, Neurology, 91, e1809, 10.1212/WNL.0000000000006469 · DOI · Paper page
- Tosun, 2017, Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals, Brain, 140, 1499, 10.1093/brain/awx046 · DOI · Paper page
- Leal, 2018, Subthreshold amyloid predicts tau deposition in aging, J Neurosci, 38, 4482, 10.1523/JNEUROSCI.0485-18.2018 · DOI · Paper page
- Bejanin, 2019, Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration, Brain, 142, 3621, 10.1093/brain/awz277 · DOI
- Lesman-Segev, 2021, Diagnostic accuracy of amyloid versus 18F-fluorodeoxyglucose positron emission tomography in autopsy-confirmed dementia, Ann Neurol, 89, 389, 10.1002/ana.25968 · DOI · Paper page
- Raman, 2022, Dynamic amyloid PET: relationships to 18F-flortaucipir tau PET measures, J Nucl Med, 63, 287, 10.2967/jnumed.120.254490 · DOI
Cited by
New landscape of the diagnosis of Alzheimer’s disease
Frisoni, G. B., Hansson, O., Nichols, E., Garibotto, V., Schindler, S. E., van der Flier, W. M., Jessen, F., Villain, N., Arenaza-Urquijo, E. M., Crivelli, L., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01294-2 · Cited by 143
Anti-Amyloid Therapies for Alzheimer’s Disease and the Amyloid Cascade Hypothesis
Fedele, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914499 · Cited by 102
Shi, Y., Zhang, R., Li, M., Xia, Y., Zhou, M., Cao, R., Zhou, Q., & Zhang, Y. (2026) · Theranostics · doi:10.7150/thno.131311
“These peptides are initially present in the form of soluble monomers, then aggregate to form oligomers and protofibrils, and end up forming insoluble plaques within the brain [3, 4].”
Metadata
- Authors
- Jagust, W. J., Teunissen, C. E., & DeCarli, C.
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2023-09
- Volume
- 22
- Issue
- 9
- Pages
- 847-857
- ISSN
- 1474-4422
- Cited by
- 71
- References
- 41
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (am, 168 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Funders
- National Institutes of Health (AG024904, AG034570, AG062542, AG072972, AG075758, NS120384)
- Health~Holland
- European Commission
- Dutch Research Council
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The complex pathway between amyloid β and cognition: implications for therapy. https://app.cochat.ai/papers/10.1016/s1474-4422(23)00128-x
- The paper
- Jagust, W. J., Teunissen, C. E., & DeCarli, C. (2023). The complex pathway between amyloid β and cognition: implications for therapy. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(23)00128-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.